正在临床试验中接受评估的埃博拉病毒病候选疫苗。
Ebola virus disease candidate vaccines under evaluation in clinical trials.
作者信息
Martins Karen A, Jahrling Peter B, Bavari Sina, Kuhn Jens H
机构信息
a United States Army Medical Research Institute of Infectious Diseases , Fort Detrick , Frederick , MD , USA.
b Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Fort Detrick , Frederick , MD , USA.
出版信息
Expert Rev Vaccines. 2016 Sep;15(9):1101-12. doi: 10.1080/14760584.2016.1187566. Epub 2016 May 27.
Filoviruses are the etiological agents of two human illnesses: Ebola virus disease and Marburg virus disease. Until 2013, medical countermeasure development against these afflictions was limited to only a few research institutes worldwide as both infections were considered exotic due to very low case numbers. Together with the high case-fatality rate of both diseases, evaluation of any candidate countermeasure in properly controlled clinical trials seemed impossible. However, in 2013, Ebola virus was identified as the etiological agent of a large disease outbreak in Western Africa including almost 30,000 infections and more than 11,000 deaths, including case exportations to Europe and North America. These large case numbers resulted in medical countermeasure development against Ebola virus disease becoming a global public-health priority. This review summarizes the status quo of candidate vaccines against Ebola virus disease, with a focus on those that are currently under evaluation in clinical trials.
丝状病毒是两种人类疾病的病原体
埃博拉病毒病和马尔堡病毒病。直到2013年，针对这些疾病的医学对策研发仅限于全球少数几个研究机构，因为由于病例数极少，这两种感染都被视为罕见病。再加上这两种疾病的高病死率，在适当控制的临床试验中评估任何候选对策似乎都不可能。然而，2013年，埃博拉病毒被确定为西非一次大规模疾病暴发的病原体，该疫情包括近3万例感染和1.1万多人死亡，还出现了病例输出到欧洲和北美的情况。这些大量病例使得针对埃博拉病毒病的医学对策研发成为全球公共卫生的优先事项。本综述总结了针对埃博拉病毒病的候选疫苗的现状，重点关注目前正在临床试验中评估的疫苗。
Zotero 插件